Newly patented bone marrow biopsy device to bolster bone cancer treatment landscape in India, says GlobalData

Sample article from our R&D/Patents

April 7, 2023 (press release) –

Bone marrow cancer is one of the most prevalent types of cancer in India, affecting a large population. Treatment options typically include chemotherapy, radiation therapy, and bone marrow transplantation. To determine these treatment options, a bone marrow biopsy is a vital diagnostic tool. Against this backdrop, the emergence of a new biopsy device is expected to boost the Indian bone cancer treatment landscape, says GlobalData, a leading data, and analytics company.

Doctors and faculty members from the Gujrat Cancer Research Institute (GCRI) and the Institute of Infrastructure Technology Research and Management (IITRAM) have recently joined hands to design a bone marrow biopsy device. It provides doctors with three indicators: identification of the bone, confirmation of device insertion into the bone, and notification in case of perforation through the opposite end of the bone, which simplifies the tissue extraction process.

GlobalData’s research reveals that India’s biopsy needle devices, which account for close to 12% of the Asia-Pacific (APAC) market in 2023, is expected to grow at a compound annual growth rate of nearly 3% through 2030.

Ayshi Ganguly, Medical Devices Analyst at GlobalData, comments: “Nerve and blood vessel damage, bone fracture, uncontrolled bleeding from the site of incision, and high chances of infection are some of the risks associated with the conventional needle bone biopsies. Some other consequences include fluid retention at the biopsy site and even over and under-extraction of tissue for examination. This newly patented device is expected to mitigate these risks associated with needle biopsies and reduce accidental damage to tissues and bones.”

The device has also been granted an Indian patent recently. Doctors can now limit the risk associated with manual or electric needles using a force-balancing mechanism that mitigates the forceful thrusting of needles into bones. This ensures safe extraction of the optimal amount of tissue for diagnosis. This device is also aided with additional depth sensors and pressure control technology to increase accuracy and efficiency.

Ganguly concludes: “The introduction of a new bone marrow biopsy device is expected to yield positive implications for medical diagnosis in India. In addition, the FDA and CE regulatory approvals in the future will help market this device across geographies. The device has the potential to disrupt the Indian bone marrow biopsy market as it scores over conventional biopsy needles and will eventually boost the bone cancer diagnosis ecosystem in India.”

Media Enquiries

If you are a member of the press or media and require any further information, please get in touch, as we're very happy to help.

* All content is copyrighted by Industry Intelligence, or the original respective author or source. You may not recirculate, redistrubte or publish the analysis and presentation included in the service without Industry Intelligence's prior written consent. Please review our terms of use.

More from our R&D/Patents Coverage
See our dashboard in action - schedule an demo
Jason Irving
Jason Irving
- SVP Enterprise Solutions -

We offer built-to-order r&d/patents coverage for our clients. Contact us for a free consultation.

About Us

We deliver market news & information relevant to your business.

We monitor all your market drivers.

We aggregate, curate, filter and map your specific needs.

We deliver the right information to the right person at the right time.

Our Contacts

1990 S Bundy Dr. Suite #380,
Los Angeles, CA 90025

+1 (310) 553 0008

About Cookies On This Site

We collect data, including through use of cookies and similar technology ("cookies") that enchance the online experience. By clicking "I agree", you agree to our cookies, agree to bound by our Terms of Use, and acknowledge our Privacy Policy. For more information on our data practices and how to exercise your privacy rights, please see our Privacy Policy.